Page last updated: 2024-09-05

sorafenib and Sarcopenia

sorafenib has been researched along with Sarcopenia in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Chao, Y; Chen, YT; Cheng, TY; Hou, MC; Huang, YH; Lee, PC1
Alsebaey, A; Aly, RA; Badran, H; Elsabaawy, MM; Ragab, A; Sabry, A1
Enomoto, N; Higuchi, M; Itakura, J; Izumi, N; Komiyama, Y; Kubota, Y; Kurosaki, M; Nakanishi, H; Okada, M; Takada, H; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Yasui, Y1
Costentin, C; Decaens, T; Diao, G; Duvoux, C; Katsahian, S; Laurent, A; Luciani, A; Mallat, A; Nault, JC; Nelson, AC; Pigneur, F; Tselikas, L1
Antoun, S; Baracos, VE; Birdsell, L; Escudier, B; Sawyer, MB1
Blanchet, B; Boudou-Rouquette, P; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Michels, J; Mir, O; Pol, S; Ropert, S; Vidal, M1

Trials

1 trial(s) available for sorafenib and Sarcopenia

ArticleYear
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:8

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Body Mass Index; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sarcopenia; Sorafenib

2010

Other Studies

5 other study(ies) available for sorafenib and Sarcopenia

ArticleYear
Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure.
    Scientific reports, 2020, 10-27, Volume: 10, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Sarcopenia; Sorafenib

2020
Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients.
    Asian Pacific journal of cancer prevention : APJCP, 2020, Nov-01, Volume: 21, Issue:11

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Prognosis; Radiofrequency Ablation; Sarcopenia; Sorafenib; Survival Rate

2020
Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.
    PloS one, 2018, Volume: 13, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Male; Portal Vein; Prognosis; Proportional Hazards Models; Sarcopenia; Serum Albumin; Sorafenib; Treatment Outcome

2018
Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:10

    Topics: Aged; Alanine; alpha-Fetoproteins; Carcinoma, Hepatocellular; Female; France; Hand-Foot Syndrome; Humans; Intra-Abdominal Fat; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sarcopenia; Sorafenib; Survival Rate; Tomography, X-Ray Computed; Triazines

2015
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.
    PloS one, 2012, Volume: 7, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sarcopenia; Sorafenib; Survival Analysis

2012